Drug
Tolebrutinib clinical trials
Also written SAR442168.
How studies write it
Studies that test it under each name
Name
Development codes
Studies by the year they started
12 studies that test it; most in 2020 (5)
| Year | Studies |
|---|---|
| 2019 | 3 |
| 2020 | 5 |
| 2021 | 1 |
| 2022 | 2 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 11 · Other 1
Sanofi (11) · National Institute of Neurological Disorders and Stroke (NINDS) (1)
Studies
Open first, then newest update. How each study uses tolebrutinib is read from its arms, and is right about nine times in ten.
Testing it · 12
- A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.Active, not recruitingPhase 3SanofiNCT06372145Written as Tolebrutinib
- Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (PERSEUS)CompletedPhase 3SanofiNCT04458051Written as Tolebrutinib
- Long Term Safety and Efficacy Study of Tolebrutinib (SAR442168) in Participants With Relapsing Multiple SclerosisCompletedPhase 2SanofiNCT03996291Written as Tolebrutinib
- Study of Excretion Balance and Pharmacokinetics of [14C]-SAR442168 in Healthy Male SubjectsCompletedPhase 1SanofiNCT04171310Written as SAR442168
- Dose-finding Study for SAR442168 in Relapsing Multiple SclerosisCompletedPhase 2SanofiNCT03889639Written as SAR442168
- Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 2)CompletedPhase 3SanofiNCT04410991Written as Tolebrutinib
- Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (HERCULES)CompletedPhase 3SanofiNCT04411641Written as Tolebrutinib
- Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 1)CompletedPhase 3SanofiNCT04410978Written as Tolebrutinib
- Study to Assess the Plasma Concentration of Tolebrutinib Given as a Tablet to Adult Participants With Renal Impairment Compared to Healthy Participants.CompletedPhase 1SanofiNCT05282030Written as tolebrutinib
- Study to Assess the Plasma Concentration of Tolebrutinib Given as a Tablet to Adult Participants With Mild Hepatic Impairment Compared to Participants With Normal Hepatic FunctionCompletedPhase 1SanofiNCT05283915Written as tolebrutinib
- Tolebrutinib, a Brain-penetrant Bruton's Tyrosine Kinase Inhibitor, for the Modulation of Chronically Inflamed White Matter Lesions in Multiple SclerosisActive, not recruitingPhase 2National Institute of Neurological Disorders and Stroke (NINDS)NCT04742400Written as tolebrutinib 60mg
- Study of the Tolerability and Pharmacokinetics of Oral Doses of SAR442168 With a Food Effect Investigation in Healthy Adult ParticipantsCompletedPhase 1SanofiNCT06106074Written as Tolebrutinib
Given in every arm · 1 — tolebrutinib is usual care beside what is tested
Codes
What other systems call tolebrutinib · ClinicalTrials.gg INT015640
- UNII (FDA) 8CZ82ZYY9XTOLEBRUTINIBConfirmed FDA, Wikidata
- Wikidata Q130337251tolebrutinibConfirmed FDA, Wikidata
- NCI Thesaurus C173549TolebrutinibOne source FDA
- DrugBank DB18715One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 8CZ82ZYY9X | TOLEBRUTINIB | Confirmed FDA, Wikidata |
| Wikidata | Q130337251 | tolebrutinib | Confirmed FDA, Wikidata |
| NCI Thesaurus | C173549 | Tolebrutinib | One source FDA |
| DrugBank | DB18715 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.